Prostate cancer topics, links and more. Now at 200+ posts!

News: Health Day, Medical News Today, ScienceDaily, Urol Times, Urotoday, Zero Cancer Papers: Pubmed (all), Pubmed (Free only), Amedeo
Journals: Eur Urol, J Urol, JCO, The Prostate Others Pubmed Central Journals (Free): Adv Urol, BMC Urol, J Endourol, Kor J Urol, Rev Urol, Ther Adv Urol, Urol Ann
Reviews: Cochrane Summaries, PC Infolink Newsletters: PCRI, US Too General Medical Reviews: f1000, Health News Review

Monday, March 5, 2007

Prostate Cancer Drug Pipeline

[updated June 4, 2007]

Here is a May 2007 list of future drugs for prostate cancer (and other
genitourinary diseases) that are in the pipeline. Although that may seem
old note that it takes many years to get through the pipeline.

and here is another shorter list (undated):

This US Too list of drugs being investigated focuses on hormone refactory prostate cancer:

This is a list of clinical trials currently underway for prostate cancer:

Some additional clinical trial sites from other countries are here:


Also see the International Standard Randomized Control Trial Number site: ISRCTN. Here is a bit of information about it taken
from the site's FAQ:

Q. What does ISRCTN mean?
A. ISRCTN stands for International Standard Randomised Controlled Trial Number. The ISRCTN scheme is a simple numeric system for the unique identification of clinical trials worldwide. In addition to randomised controlled trials, the ISRCTN Register will also accept registration of other forms of studies designed to assess the efficacy of healthcare interventions.

Q. What is the aim of the ISRCTN scheme?
A. The aim of the ISRCTN scheme is to simplify the identification of trials and provide a unique number that can be used to track all publications and reports resulting from each trial.

Q. Who owns the ISRCTN Register?
A. The ISRCTN Register is owned by ISRCTN - a not-for-profit organisation.

The Phases used in clinical trials are described here:

According to Table 4 of the following report prepared by the US Federal Trade
Commission, drugs in Phase I, II and III have probabilities of succeeding to
the point they enter the US market of 12%, 17% and 38%, respectively, although the probabilities are somewhat larger for big pharma and for biological based

This link gives additional background information on clinical trials that may be useful in reading the above:

No comments: